This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Merck Asks FDA to Authorize Promising Covid-19 Pill
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Merck Asks FDA to Authorize Promising Covid-19 Pill
Business

Merck Asks FDA to Authorize Promising Covid-19 Pill

Editorial Board Published October 11, 2021
Share
Merck Asks FDA to Authorize Promising Covid-19 Pill
SHARE

Merck & Co. and partner Ridgeback Biotherapeutics LP said Monday they have filed an application asking U.S. health regulators to authorize their Covid-19 pill, the next step toward adding a long-sought drug for use at home.

Contents
Newsletter Sign-upCoronavirus Briefing and Health WeeklyCovid-19 Vaccines

The filing comes shortly after data from a late-stage study showed that the antiviral drug, molnupiravir, cut the risk of hospitalization or death by about 50% in high-risk people with mild to moderate Covid-19. 

The U.S. Food and Drug Administration could clear the antiviral in the coming weeks and possibly in time for what some public-health experts say could be another virulent winter, especially among people who aren’t vaccinated.

“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” Merck Chief Executive Robert Davis said.

Unlike Covid-19 vaccines and some other drugs for the disease that target the spike protein, molnupiravir works by targeting a part of the virus that helps it reproduce.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


Doctors and patients have been waiting for an effective pill that would be easy to take at home, with the goal of preventing a case from turning severe and requiring hospitalization.

Antibody drugs, like one from Regeneron Pharmaceuticals Inc., have been authorized for use in Covid-19 patients before they are hospitalized. These drugs have shown to be more effective in clinical trials, but they require infusions and are tougher to administer.

The Merck-Ridgeback pill, if authorized, would be the first oral antiviral for Covid-19. A course of treatment is 40 pills, eight daily for five days, started within five days of showing symptoms.

The companies have said that the rate of side effects in study subjects who got molnupiravir and those who got a placebo was similar.

The findings were based on an early look at the data from a pivotal trial that is scheduled to finish in November.

Merck plans to manufacture 10 million courses of treatment by the end of the year and has already begun production. The Kenilworth, N.J.-based drugmaker has a $1.2 billion deal with the U.S. to provide 1.7 million courses of treatment, should regulators clear it for use.

Merck also has said it would make molnupiravir available globally and has licensing agreements with generic drugmakers, including Dr. Reddy’s Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. , to ensure the drug’s availability to low-income countries.

The company also said it plans to peg pricing for molnupiravir to the wealth of the country buying it, based on World Bank criteria, to help expand access to low- and middle-income countries.

Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ

Remdesivir, from Gilead Sciences Inc., is the only FDA-approved antiviral but its use is restricted to hospitalized patients.

The companies announced molnupiravir’s positive results this month after an early look at the data found that it helped unvaccinated people who were at high risk of becoming sick. High risk was defined as having at least one characteristic associated with severe disease or death, such as old age, obesity or diabetes.

The emergency-use authorization requested by Merck and Ridgeback is different from a full approval, permitting manufacturers to distribute products during public-health emergencies based on the best available evidence at the time.

Ridgeback licensed molnupiravir from a not-for-profit biotech company owned by Emory University and last year joined with Merck on its development.

Other drugmakers are working on Covid-19 antivirals, including Roche Holding AG and partner Atea Pharmaceuticals Inc., as well as Pfizer Inc., though they haven’t yet announced any results from late-stage studies.

Covid-19 Vaccines

Write to Jared S. Hopkins at jared.hopkins@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article The Latest Slump in Car Sales Has Winners and Losers The Latest Slump in Car Sales Has Winners and Losers
Next Article Bing Crosby’s heirs sell stake in estate to boost his work Bing Crosby’s heirs sell stake in estate to boost his work

Editor's Pick

I attempted Google’s new Search Dwell function and ended up debating an AI about books

I attempted Google’s new Search Dwell function and ended up debating an AI about books

Google’s new Search Dwell function lets customers maintain real-time voice conversations with an AI-powered model of Search The Gemini-powered AI…

By Editorial Board 6 Min Read
Valkyries convey again Chen and Bibby as EuroBasket hits roster
Valkyries convey again Chen and Bibby as EuroBasket hits roster

The Valkyries signed 2025 third-round draft decide Kaitlyn Chen and ahead Chloe…

3 Min Read
AI at Scale: Mohammed’s Revolutionary Architecture Behind the World’s Fastest Website Builder
AI at Scale: Mohammed’s Revolutionary Architecture Behind the World’s Fastest Website Builder

In an extraordinary technological breakthrough, Abdul Muqtadir Mohammed has fundamentally transformed how…

7 Min Read

Oponion

No signal of break-in at Birmingham dwelling the place man discovered shot within the head, police say

No signal of break-in at Birmingham dwelling the place man discovered shot within the head, police say

Authorities have launched the identify of a person who was…

June 2, 2025

NYT Strands in the present day — my hints, solutions and spangram for Monday, January 20 (sport #323)

Strands is the NYT’s newest phrase…

January 20, 2025

SEC Opens Probe Into Tesla Involving Solar-Cell Activity

The U.S. Securities and Exchange Commission…

December 6, 2021

Companies Prepare for Fallout From Cyberattacks Against Ukraine

Businesses including utilities, manufacturers and financial-services…

January 25, 2022

Single-family home sells in Danville for $1.9 million

Bay Space House Report 13 Ocho…

January 24, 2025

You Might Also Like

Exploring Royal Mail’s Use of Ambient IoT Know-how with Wiliot
Business

Exploring Royal Mail’s Use of Ambient IoT Know-how with Wiliot

Eric Casavant: The partnership is a three-phase effort, undertaken by Royal Mail and Wiliot to digitize automobiles, amenities, and supply…

6 Min Read
Airgain Launches Business’s First Commercially Obtainable Cat 1 bis Embedded Modem Licensed for Buyer Finish-Functions
Business

Airgain Launches Business’s First Commercially Obtainable Cat 1 bis Embedded Modem Licensed for Buyer Finish-Functions

New addition to the NimbeLink Skywire™ household simplifies world IoT deployments with sooner integration, decrease prices, and seamless {hardware} migration.…

4 Min Read
From Blind Spots to Insights: Smarter Asset Monitoring
Business

From Blind Spots to Insights: Smarter Asset Monitoring

By Ohad Peled, Product Advertising Supervisor at Sony Semiconductor Israel. Over the previous couple of years, asset monitoring has emerged…

9 Min Read
Contained in the Physique: How Ingestible Sensors Are Shaping the Way forward for Healthcare
Business

Contained in the Physique: How Ingestible Sensors Are Shaping the Way forward for Healthcare

Lately, the speedy evolution of expertise has dramatically remodeled healthcare. From wearable devices to AI-powered diagnostics, innovation has been on…

12 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?